Post by ronykimm on Dec 29, 2021 8:09:41 GMT -5
Brentuximab vedotin is introduced and aimed to treat recipients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma, which is a type of T cell non-Hodgkin lymphoma. The brentuximab vedotin should be administered as an infusion into a vein over around 30 minutes. Treatment with brentuximab is not recommended at the same time as the therapy with Bleomycin.